Drug Price Debate May Not Hinder Biotech ETFs After All

The issue of pharmaceuticals pricing reform — a long-time favorite discussion on Capitol Hill — is gaining momentum, and some healthcare assets are bearing that burden. For example, the ALPS Medical Breakthroughs ETF (SBIO) is lower by 2.35% over the past week as investors fret about the specter of...